SCHEMBL3369060

SCHEMBL3369060

CNC(=O)Cc1ccc(OC)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.76
TDP1 Q9NUW8 1/20 0.69
SMN1; SMN2 Q16637 3/20 0.61
NPC1 O15118 1/20 0.61
LMNA P02545 1/20 0.61
EPHX2 P34913 1/20 0.59
ALDH1A1 P00352 4/20 0.58
MAPT P10636 2/20 0.58
RAB9A P51151 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CNR2 P34972 2/20 0.56
EGFR P00533 2/20 0.56
ERCC1 P07992 1/20 0.56
ERCC4 Q92889 1/20 0.56
ERBB2 P04626 1/20 0.56
NLRP3 Q96P20 1/20 0.55
SAE1 Q9UBE0 1/20 0.54
UBA2 Q9UBT2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10684986 0.85 HTT (0.76) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL10928682 0.83 HTT (0.63) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL169824 0.83 TDP1 (0.76) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL2494898 0.83 HTT (0.73) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL4928502 0.83 HTT (0.73) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL3369054 0.83 HTT (0.73) HTTTDP1SMN1; SMN2NPC1LMNA
Hydrochloric Acid SCHEMBL10932165 0.82 HTT (0.61) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL7905681 0.81 HTT (0.71) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL2450845 0.81 HTT (0.71) HTTTDP1SMN1; SMN2NPC1LMNA
SCHEMBL12228278 0.81 F2RL1 (0.69) HTTSMN1; SMN2ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP claimed
WO-2024052356-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-14 WO claimed
EP-1673349-B1 BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S BIO PTE LTD (SG) 2010-06-30 EP claimed
EP-1673349-A4 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S BIO PTE LTD (SG) 2008-01-23 EP claimed
JP-2007505942-A 2007-03-15 JP claimed
US-20070043043-A1 Benzimidazole derivates: preparation and pharmaceutical applications S*BIO PTE LTD. (SG) 2007-02-22 US claimed
EP-1673349-A1 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*Bio Pte Ltd (SG) 2006-06-28 EP claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
WO-2005028447-A1 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-03-31 WO claimed
EP-4583860-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2025-07-16 EP disclosed
WO-2024052356-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-14 WO disclosed
CN-109369506-B Method for selectively N-methylating secondary amide 广东石油化工学院 2022-05-31 CN disclosed
US-10736881-B2 Benzimidazole derivatives: preparation and pharmaceutical applications MEI PHARMA, INC. (US) 2020-08-11 US disclosed
US-20190282547-A1 BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD. (SG) 2019-09-19 US disclosed
US-20050090509-A1 Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents Agouron Pharmaceuticals,Inc. 2005-04-28 US disclosed
WO-2005028447-A1 BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-03-31 WO disclosed
US-20040167119-A1 2-(aminomethyl) arylamide analgesics PHARMACOPEIA, INC (US) 2004-08-26 US disclosed
WO-2004071445-A2 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-26 WO disclosed
WO-2004071445-A2 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-26 WO disclosed
CN-1284878-A Drugs augmenting NKT cells FUJISAWA PHARMACEUTICAL CO (JP) 2001-02-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190282547-A1 BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS HDAC5, HDAC1, HDAC8 HTT 1179/4885TDP1 1491/4885SMN1; SMN2 3612/4885
US-20050090509-A1 Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents CCNA1, PGF, CCNA2 HTT 3821/4885TDP1 226/4885SMN1; SMN2 3218/4885
US-20070043043-A1 Benzimidazole derivates: preparation and pharmaceutical applications HDAC5, HDAC1, HDAC4 HTT 783/4885TDP1 1540/4885SMN1; SMN2 3669/4885
US-10736881-B2 Benzimidazole derivatives: preparation and pharmaceutical applications HDAC5, HDAC1, HDAC8 HTT 1179/4885TDP1 1491/4885SMN1; SMN2 3612/4885
US-20040167119-A1 2-(aminomethyl) arylamide analgesics OPRL1, OPRM1, OPRK1 HTT 1195/4885TDP1 3650/4885SMN1; SMN2 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.